Ultragenyx Pharmaceutical Inc (RARE) Given New $80.00 Price Target at Wedbush

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) had its price objective decreased by Wedbush from $88.00 to $80.00 in a research note released on Thursday morning. Wedbush currently has a buy rating on the biopharmaceutical company’s stock.

RARE has been the topic of a number of other reports. Cowen and Company reissued a buy rating on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 17th. Jefferies Group LLC reissued a buy rating and set a $109.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 17th. Piper Jaffray Companies restated a buy rating and set a $96.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 30th. Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a hold rating to a sell rating in a report on Wednesday, January 4th. Finally, Citigroup Inc lowered shares of Ultragenyx Pharmaceutical from a neutral rating to a sell rating in a report on Wednesday, November 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $83.14.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up 1.89% during mid-day trading on Thursday, hitting $62.04. The stock had a trading volume of 887,963 shares. The stock’s market cap is $2.59 billion. Ultragenyx Pharmaceutical has a 12-month low of $46.52 and a 12-month high of $91.35. The company has a 50-day moving average of $72.59 and a 200-day moving average of $72.33.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by $0.03. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.05 million. The firm’s quarterly revenue was up 4900.0% on a year-over-year basis. During the same quarter last year, the company posted ($1.42) earnings per share. On average, analysts anticipate that Ultragenyx Pharmaceutical will post ($7.07) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/04/20/ultragenyx-pharmaceutical-inc-rare-price-target-cut-to-80-00-by-analysts-at-wedbush-updated-updated.html.

In related news, CFO Shalini Sharp sold 12,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $80.14, for a total transaction of $961,680.00. Following the completion of the sale, the chief financial officer now owns 63,887 shares of the company’s stock, valued at approximately $5,119,904.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Theodore Alan Huizenga sold 2,500 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, March 9th. The stock was sold at an average price of $86.34, for a total transaction of $215,850.00. The disclosure for this sale can be found here. Insiders have sold a total of 26,500 shares of company stock valued at $2,258,730 in the last ninety days. 10.10% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. BlackRock Investment Management LLC increased its stake in Ultragenyx Pharmaceutical by 0.6% in the third quarter. BlackRock Investment Management LLC now owns 153,399 shares of the biopharmaceutical company’s stock worth $10,882,000 after buying an additional 846 shares in the last quarter. BlackRock Advisors LLC increased its stake in Ultragenyx Pharmaceutical by 0.6% in the third quarter. BlackRock Advisors LLC now owns 345,143 shares of the biopharmaceutical company’s stock worth $24,484,000 after buying an additional 2,114 shares in the last quarter. DIAM Co. Ltd. increased its stake in Ultragenyx Pharmaceutical by 486.7% in the third quarter. DIAM Co. Ltd. now owns 21,017 shares of the biopharmaceutical company’s stock worth $1,443,000 after buying an additional 17,435 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Ultragenyx Pharmaceutical by 6.9% in the third quarter. JPMorgan Chase & Co. now owns 281,549 shares of the biopharmaceutical company’s stock worth $19,974,000 after buying an additional 18,212 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in Ultragenyx Pharmaceutical by 8.4% in the third quarter. UBS Asset Management Americas Inc. now owns 21,319 shares of the biopharmaceutical company’s stock worth $1,513,000 after buying an additional 1,660 shares in the last quarter. 96.35% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

5 Day Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply